Pilot Study of Natalizumab in the Treatment of Patients With Inclusion Body Myositis

Trial Profile

Pilot Study of Natalizumab in the Treatment of Patients With Inclusion Body Myositis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Inclusion body myositis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Feb 2017 Planned primary completion date changed from 1 May 2016 to 1 Nov 2017.
    • 08 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Apr 2016 Interim results (n=2) presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top